Race Oncology: Secures human ethics trial approval

Race Oncology Secures human ethics trial approval

• Race Oncology (RAC) receives human ethics approval for the next stage of its clinical trial of Zantrene in breast cancer patients
• The company received the approval from the Hunter New England Human Research Ethics Committee for the observational stage of a planned phase 1/2b cardioprotection clinical program using Zantrene
• The company must now submit and receive research institutional governance approval before patients can be enrolled and treated in the study
• Race says the human trials will be fully funded from its December 2021 capital raise
• RaceOncology is up 3.99 per cent, trading at $1.96 at 2:51 pm AEDT